NASDAQ:CRVS
Corvus Pharmaceuticals
- Stock
locale
United Statesmarket
STOCKSindustry
Biotechnologywebsite
www.corvuspharma.comipo date
Mar 23, 2016
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covale...Show More
Earnings
Earnings Release in 10 daysEarnings per Share (Estimate*)
Revenue (Estimate*)
*Estimate based on analyst consensus